Pramodini Medicare SME IPO GMP History | Listing Price ₹120 & Kostak Rate
Pramodini Medicare SME IPO has been listed on August 19, 2026 at a listing price of ₹120, against the issue price of ₹118 — a gain of ₹2 (+1.69%). The GMP peaked at ₹0 on 8 August 2026 and reached a low of ₹0 on 8 August 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Pramodini Medicare SME IPO raised ₹69.04 Cr. through its IPO at a price band of ₹110 to ₹118 per share, with a lot size of 1200 shares. The IPO was open for subscription from 12 Aug 2026 to 14 Aug 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 26 Aug, 8:33 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 08 Aug 2026 | ₹ 0 | — | -- | ₹ 0 | ₹ 0 |
| 06 Aug 2026 | ₹ 0 | — | -- | ₹ 0 | ₹ 0 |
| 05 Aug 2026 | ₹ 0 | — | -- | ₹ 0 | ₹ 0 |
Pramodini Medicare SME IPO dates
Key dates from opening to listing. Today is 19 September.
- Open 12 Aug 2026
- Close 14 Aug 2026
- Allotment 17 Aug 2026
- Refund/credit 18 Aug 2026
- Listing 19 Aug 2026
Pramodini Medicare SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹118 |
|---|---|
| Listing gain / loss | +₹2 per share |
| Listing date | 19 Aug, 2026 |
| Actual listing price | ₹120 (+1.69%) |
Is Pramodini Medicare SME IPO GMP reliable?
Grey market premium for Pramodini Medicare SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Pramodini Medicare SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Pramodini Medicare SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Pramodini Medicare SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Pramodini Medicare SME IPO
Pramodini Medicare Limited was started in 2000. It is a diagnostic services company. It runs radiology services such as MRI, CT scan, X-ray, ultrasound with colour doppler, mammography and Dexa scan, clinical laboratory services such as pathology, microbiology, immunology and biochemistry, and nuclear medicine services such as PET-CT, SPECT and nuclear therapy.
The company works through four models. Under the public private partnership model it runs diagnostic centres inside government hospitals and medical colleges on long term agreements. Under the private private model it runs centres inside private hospitals. It also works with central government PSUs, and it runs some of its own standalone centres and labs. It has a 24x7 teleradiology unit and a processing laboratory at Vijayawada.
As on 4 August 2026 the company ran 16 diagnostic centres across seven states, serving government hospitals, private hospitals, PSUs, medical colleges and individual patients in Tier I, Tier II and Tier III cities. As on 31 March 2026 it had 161 permanent employees.
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 8
- 01FY2026 was a strong year. Total income grew 64% from Rs 38.55 crore to Rs 63.38 crore and profit after tax grew 56% from Rs 11.14 crore to Rs 17.38 crore.
- 02Operating margin is high. EBITDA was Rs 30.90 crore on total income of Rs 63.38 crore in FY2026, which is close to half of the income.
- 03Profit has grown every year, from Rs 7.14 crore in FY2024 to Rs 11.14 crore in FY2025 and Rs 17.38 crore in FY2026.
- 04The PPP model with government hospitals gives long term contracts and a steady flow of patients without spending on marketing.
- 05The business is spread over 16 centres in seven states, so it does not depend on one city or one hospital.
- 06It offers radiology, laboratory and nuclear medicine together, which is a wider range than most small diagnostic chains.
- 07Rs 45.15 crore of the issue money is for buying medical equipment for existing and new centres, which will add earning capacity.
- 08Net worth improved from Rs 24.75 crore in FY2024 to Rs 53.15 crore in FY2026.
Risks · 8
- 01Borrowing went up 65% in one year, from Rs 10.81 crore to Rs 17.85 crore.
- 02A part of the money is kept for general corporate purposes and an unidentified acquisition. The company has not named the target, so investors do not know where that money will go.
- 03The PPP and hospital contracts run on MOUs that come up for renewal. If a government hospital does not renew or gives the contract to another operator, that centre income stops.
- 04Diagnostics needs heavy spending on machines. MRI, CT and PET-CT equipment is costly and becomes outdated, so capital spending never really stops.
- 05A large part of the business comes from government hospitals and PSUs, where payments can be delayed and rates are fixed by tender.
- 06The company is small, with 161 employees and 16 centres, and competes with large national diagnostic chains that have better brand pull and lower cost per test.
- 07Promoter holding will come down from 85.71% to 62.64% after the issue.
- 08This is an SME issue. One lot is 1,200 shares, which is about Rs 1.41 lakh at the upper band of Rs 118, and SME shares usually trade in low volume after listing.
Frequently asked
What is the GMP of Pramodini Medicare SME IPO?
The current Grey Market Premium (GMP) of Pramodini Medicare SME IPO is not yet started or active in the market.
What is the Kostak Price of Pramodini Medicare SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Pramodini Medicare SME IPO is currently not available.
What is the Subject to Sauda Price of Pramodini Medicare SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Pramodini Medicare SME IPO?
Pramodini Medicare SME IPO listed on August 19, 2026 at ₹120, against the issue price of ₹118 — a gain of +1.69%.
How did the GMP of Pramodini Medicare SME IPO trend before listing?
The GMP of Pramodini Medicare SME IPO was stable in its final days before listing. The GMP peaked at ₹0 on 8 August 2026. View the day-wise table above for the complete GMP history.
Explore Pramodini Medicare SME IPO further
For a complete picture before making your investment decision, explore these resources.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
